// App-Quantinova.ai

2319 : Selinexor, a selective inhibitor of nuclear export (SINE), enhances the in vivo efficacy of checkpoint blockade with antibodies targeting CTLA4 or PD-1/PD-L1 in melanoma

Researchers

Presenter

  • Matthew R. Farren

Principal Investigators

  • Reena Shakya

  • Rebecca Hennessey

  • Thomas Mace

  • Jennifer Yang

  • Omar Elnaggar

  • Gregory Young

  • Yosef Landesman

  • Robert Carlson

  • Sivan Elloul

  • Marsha Crochiere

  • Christin Burd

  • Gregory B. Lesinski

Medical Centers

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Karyopharm Therapeutics, Newton, MA

Locations

  • United States

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Exportin 1

  • Signal Transducer And Activator Of Transcription 1

  • Signal transducer and activator of transcription 3

  • Type 1 T helper

Drug/Treatment

  • Anti-CTLA4

  • Selinexor

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved